Along with tumor progression, the bone marrow microenvironment is skewed in multiple
myeloma (MM), which underlies the unique pathophysiology of MM and confers …

Receptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is
upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically …

Immunotherapy is revolutionizing the treatment paradigm for multiple myeloma (MM).
Interferon (IFN)-γ is essential for immune responses, whereas immune checkpoint …

Summary Proviral Integrations of Moloney virus 2 (PIM 2) is overexpressed in multiple
myeloma (MM) cells, and regarded as an important therapeutic target. Here, we aimed to …

Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine catabolism that acts as a
novel regulator of adipogenesis. In pathological states, xanthine oxidoreductase activity …

Multiple myeloma (MM) preferentially expands and acquires drug resistance in the bone
marrow (BM). We herein examined the role of histone deacetylase 1 (HDAC1) in the …

In marine ecosystems, the avid binding of iron (Fe) to organic ligands influences Fe
bioavailability in seaweed. This study aimed to elucidate Fe's biological availability to …

Objectives Muscle strength decline is reported to predict mortality in many cancers.
However, there is little knowledge of the relation between muscle strength decline and …

Objectives Aberrant NLRP3 inflammasome activation has been demonstrated in rheumatoid
arthritis (RA), which may contribute to debilitating inflammation and bone destruction. Here …

Additional supporting information may be found online in the Supporting Information section
at the end of the article. Table SI. Ion AmpliSeqTM hematology panel (custom design …